Results 41 to 50 of about 1,618 (187)
Scientific Reports, 2017 The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the alteration of the structure, the newest drug is capable of combining more molecular targets and present higher affinity to the ...
Jiaming Wang +6 more
doaj +1 more source
BMC Ophthalmology, 2021 Background The use of Spectral domain optical coherence tomography (SD-OCT) to evaluate the predictors of visual acuity-recovery in patients treated with conbercept for macular edema (ME) secondary to central retinal vein occlusion (CRVO) has rarely been
Qi Zhang +8 more
doaj +1 more source
Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy [PDF]
International Journal of Ophthalmology, 2021 AIM: To compare the safety and efficacy of conbercept intravitreal injection and half-dose photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). METHODS: This study was retrospective.
Jian-Bo Mao +9 more
doaj +1 more source
Intravitreous injection of conbercept for bullous retinal detachment: A case report
World Journal of Clinical Cases, 2022 Diffuse retinal pigment epitheliopathy (DRPE) associated with bullous retinal detachment is a severe variant of DRPE that is frequently misdiagnosed and often improperly treated.A 36-year-old female patient complained of "painless vision decline in the left eye with obscuration for 10 d".
Xiang, Xiao-Li +3 more
openaire +2 more sources
The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury
Journal of Ophthalmology, 2021 Purpose. To evaluate the effects of intravitreal anti-VEGF agents in a rabbit model of open-globe injury (OGI). Methods. OGI was induced in the right eyes of 75 Belgian rabbits by making 5 mm circumferential incision placed 6 mm behind the limbus.
Xiao Zhao +10 more
doaj +1 more source
Real-world outcomes of two-year Conbercept therapy for diabetic macular edema
International Journal of Ophthalmology, 2021 AIM: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC). METHODS: The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN).
Yong Cheng, Mingwei Zhao, Tong Qian
openalex +5 more sources
Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography [PDF]
BMC Ophthalmology, 2020 Abstract Background Varying degrees of macular ischemia generally occur in diabetic retinopathy (DR). This study aims to evaluate the effect of conbercept with 3+ pro re nata (PRN) on macular perfusion status in patients with diabetic macular edema (DME) and quantitatively assess changes in ...
Ziyi Zhu +6 more
openaire +3 more sources
Implantable Drug Delivery Systems for Skeletal Muscles and Eyes
Advanced NanoBiomed Research, EarlyView.This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov +8 more
wiley +1 more source
BMC Ophthalmology, 2017 Background To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. Methods This was a retrospective study.
Yule Xu +4 more
doaj +1 more source
Interdisciplinary Medicine, EarlyView.Under hyperglycemic conditions, mitochondrial dysfunction in retinal endothelial cells triggers excessive reactive oxygen species/reactive nitrogen species production, barrier protein degradation, and endothelial barrier breakdown in diabetic retinopathy.
Siyu Gui +12 more
wiley +1 more source